更新于：2024-05-01

L-HBsAg

乙型肝炎病毒表面抗原

更新于：2024-05-01

基本信息

别名

L glycoprotein、L-HBsAg、Large envelope protein

+ [5]

简介

The large envelope protein exists in two topological conformations, one which is termed 'external' or Le-HBsAg and the other 'internal' or Li-HBsAg. In its external conformation the protein attaches the virus to cell receptors and thereby initiating infection. This interaction determines the species specificity and liver tropism. This attachment induces virion internalization predominantly through caveolin-mediated endocytosis. The large envelope protein also assures fusion between virion membrane and endosomal membrane. In its internal conformation the protein plays a role in virion morphogenesis and mediates the contact with the nucleocapsid like a matrix protein. The middle envelope protein plays an important role in the budding of the virion. It is involved in the induction of budding in a nucleocapsid independent way. In this process the majority of envelope proteins bud to form subviral lipoprotein particles of 22 nm of diameter that do not contain a nucleocapsid.

关联

项与 L-HBsAg 相关的药物

Human hepatitis B immunoglobulin(Biotest Pharma GmbH)

靶点

L-HBsAg

作用机制

L-HBsAg抑制剂 [+1]

在研机构

Biotest Pharma GmbH

原研机构

Biotest Pharma GmbH

在研适应症

乙型肝炎

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

欧盟 [+3]

首次获批日期2009-11-30

Tobevibart

靶点

L-HBsAg

作用机制

L-HBsAg抑制剂 [+1]

在研机构

Vir Biotechnology, Inc. [+3]

原研机构

Vir Biotechnology, Inc.

在研适应症

慢性丁型肝炎 [+2]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

TVAX-008

重组乙型肝炎病毒表面抗原（远大赛威信）

靶点

HBcrAg x L-HBsAg

作用机制

HBcrAg抑制剂 [+2]

在研机构

远大赛威信生命科学（南京）有限公司

原研机构

远大赛威信生命科学（南京）有限公司

在研适应症

慢性乙型肝炎

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

项与 L-HBsAg 相关的临床试验

NCT06216470 / Recruiting临床2期

Phase II Investigator-Initiated Study to Understand the Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection

This is a Phase II Investigator-Initiated Study to understand the vaccinal effect of HBsAg monoclonal Ab VIR-3434 in chronic hepatitis B infection.
The purpose of this study is to test VIR-3434, an experimental drug that specifically targets the HBsAg of hepatitis B virus, to clear it from the body.
This is an open label study and there is no placebo used in this study. All participants will receive the VIR-3434 for 48 weeks and then follow up in the study for 48 weeks. A total duration of approximately 104 weeks including screening period for the entire study.

开始日期2024-03-13

申办/合作机构

University Health Network

CTR20233101 / Active, not recruiting临床1期

一项评估 BRII-877（VIR-3434）在中国健康成人受试者中的安全性、耐受性和药代动力学的随机、双盲、安慰剂对照、单次给药 I 期研究

评估 BRII-877 在中国健康成人受试者中的安全性、耐受性和药代动力学，旨在确定 BRII-877 在中国健康成人受试者与在中国大陆以外进行的研究的受试者之间安全性、耐受性和 PK 的可比性

开始日期2023-10-30

申办/合作机构

无锡药明生物技术股份有限公司

[+1]

CTR20232864 / Active, not recruiting临床2期

一项评估 BRII-835（VIR-2218）与聚乙二醇干扰素α（PEG-IFNα）联合治疗慢性乙型肝炎病毒（HBV）感染的有效性和安全性的 II 期、多中心、随机、开放标签研究

本研究旨在评价 BRII-835 和 PEG-IFNα 联合治疗在接受 NRTI 背景治疗的慢性 HBV 感染非肝硬化受试者中的有效性和安全性。

开始日期2023-10-20

申办/合作机构

腾盛博药医药技术(北京)有限公司

[+2]

100 项与 L-HBsAg 相关的临床结果

登录后查看更多信息

100 项与 L-HBsAg 相关的转化医学

登录后查看更多信息

0 项与 L-HBsAg 相关的专利（医药）

登录后查看更多信息

621

项与 L-HBsAg 相关的文献（医药）

2024-01-30·Heliyon

Up regulation of serum L fucose glycoprotein as a diagnostic biomarker for dysplasia in oral sub mucous fibrosis patients.

Article

作者: Sunil Kumar Vaddamanu ; Ravinder S Saini ; Bhavana T Veerabasavaiah ; Fahad Hussain Alhamoudi ; AbdulKhaliq Ali F Alshadidi ; Antonino Lo Giudice ; Marco Cicciù ; Giuseppe Minervini

Glycoproteins, essential for cellular functions, contain monosaccharides like Levo-fucose, crucial for cell communication. Recent research highlights serum L-fucose as a potential biomarker for early detection of malignancies. Typically, serum L-fucose levels are low but rise with malignancy. This study evaluates serum L-fucose as an early biomarker in oral submucous fibrosis (OSMF) patients.

Aim:

Assess serum L-fucose's diagnostic potential for dysplasia in OSMF patients.

Objectives:

Determine the Association between Serum L Fucose Glycoprotein Levels and Dysplasia in OSF Patients.Evaluate the Diagnostic Accuracy of Serum L Fucose Glycoprotein as a Biomarker for OSF-Related Dysplasia.

Methodology:

Over a span of two years, this study encompassed 80 subjects, aged between 18 and 60 years, who were clinically and histopathologically identified as OSMF patients, with or without dysplastic alterations. From each participant, 5 ml of blood was collected. Following centrifugation to separate the serum, the samples were analyzed to determine the levels of Levo-fucose.

Statistical analysis:

Using SPSS (version 17.0), serum L-Fucose levels of the case group were compared to the control group using ANOVA. Frequencies were analyzed with the chi-square test, and Tukey's Test was used for multiple comparisons. Significance was set at p < 0.01.

Results:

The analysis revealed a statistically significant disparity in the mean serum L-Fucose levels between the two groups (p < 0.01). Notably, Group II patients (those with OSMF and dysplasia) exhibited markedly elevated mean serum L-fucose levels.

Conclusion:

Elevated serum L-Fucose levels were observed in OSMF patients with dysplasia. Harmful habits, especially gutkha chewing, were linked to Oral Squamous Cell Carcinoma onset. Serum L-fucose can be a reliable marker for evaluating precancerous conditions.

2024-01-25·BMC biotechnology

Characterization, modeling, and anticancer activity of L.arginase production from marine Bacillus licheniformis OF2.

Article

作者: Manal S Selim ; Marwa M Mounier ; Sayeda A Abdelhamid ; Ahmed Abdelghani Hamed ; Mostafa M Abo Elsoud ; Sahar S Mohamed

BACKGROUND:

L-arginase, is a powerful anticancer that hydrolyzes L-arginine to L-ornithine and urea. This enzyme is widely distributed and expressed in organisms like plants, fungi, however very scarce from bacteria. Our study is based on isolating, purifying, and screening the marine bacteria that can produce arginase.

RESULTS:

The highest arginase producing bacteria will be identified by using microbiological and molecular biology methods as Bacillus licheniformis OF2. Characterization of arginase is the objective of this study. The activity of enzyme was screened, and estimated beside partial sequencing of arginase gene was analyzed. In silico homology modeling was applied to generate the protein's 3D structure, and COACH and COFACTOR were applied to determine the protein's binding sites and biological annotations based on the I-TASSER structure prediction. The purified enzyme was undergone an in vitro anticancer test.

CONCLUSIONS:

L-arginase demonstrated more strong anti-cancer cells with an IC50 of 21.4 ug/ml in a dose-dependent manner. L-arginase underwent another investigation for its impact on the caspase 7 and BCL2 family of proteins (BCL2, Bax, and Bax/Bcl2). Through cell arrest in the G1/S phase, L-arginase signals the apoptotic cascade, which is supported by a flow cytometry analysis of cell cycle phases.

2023-12-01·Virulence

hnRNPA1 impedes snakehead vesiculovirus replication via competitively disrupting viral phosphoprotein-nucleoprotein interaction and degrading viral phosphoprotein.

Article

作者: An-Qi Liu ; Xiangmou Qin ; Hui Wu ; Hao Feng ; Yong-An Zhang ; Jiagang Tu

Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) plays an important role in regulating the replication of many viruses. However, it remains elusive whether and how hnRNPA1 regulates fish virus replication. In this study, the effects of twelve hnRNPs on the replication of snakehead vesiculovirus (SHVV) were screened. Three hnRNPs, one of which was hnRNPA1, were identified as anti-SHVV factors. Further verification showed that knockdown of hnRNPA1 promoted, while overexpression of hnRNPA1 inhibited, SHVV replication. SHVV infection reduced the expression level of hnRNPA1 and induced the nucleocytoplasmic shuttling of hnRNPA1. Besides, we found that hnRNPA1 interacted with the viral phosphoprotein (P) via its glycine-rich domain, but not with the viral nucleoprotein (N) or large protein (L). The hnRNPA1-P interaction competitively disrupted the viral P-N interaction. Moreover, we found that overexpression of hnRNPA1 enhanced the polyubiquitination of the P protein and degraded it through proteasomal and lysosomal pathways. This study will help understanding the function of hnRNPA1 in the replication of single-stranded negative-sense RNA viruses and providing a novel antiviral target against fish rhabdoviruses.

项与 L-HBsAg 相关的新闻（医药）

2023-10-07

·生物谷

耐甲氧西林金黄色葡萄球菌生物被膜的高效精准治疗取得新进展

华中农大动物科学技术学院、动物医学院精准兽药创制与环境消减技术开发团队巧妙设计了具有级联光动力疗法和营养免疫疗法协同作用的精准纳米系统，以新型的抗菌机制高效抗生物被膜感染，相关成果以“Ta 华中农大动物科学技术学院、动物医学院精准兽药创制与环境消减技术开发团队巧妙设计了具有级联光动力疗法和营养免疫疗法协同作用的精准纳米系统，以新型的抗菌机制高效抗生物被膜感染，相关成果以“Targeting and Arginine-driven Synergizing Photodynamic Therapy with Nutritional Immunotherapy Nanosystems for Combating MRSA Biofilms”为题发表在Science advances上。本研究以PCN-224为光动力平台，开发一种靶向耐甲氧西林金黄色葡萄球菌生物被膜的精氨酸驱动的光动力与营养免疫协同治疗的复合纳米系统，并系统研究了该复合纳米系统对生物被膜的杀伤活性及其作用机制。耐甲氧西林金黄色葡萄球菌（MRSA）是一种重要的人兽共患病原菌。MRSA可以利用生物被膜逃避宿主免疫系统和抗菌药物的杀伤作用而导致顽固性感染，严重威胁人类健康，也给畜牧业造成了巨大的经济损失。常规抗菌药由于其非特异性分布和生物被膜屏障常常导致其疗效低下，并极易诱导细菌耐药性。因此，迫切需要开发具有高效抗生物被膜作用且不易诱导耐药性的新型治疗策略。光动力疗法通过产生活性氧实现对细菌的非特异性杀伤且不易诱导细菌耐药性。为此，本研究巧妙设计了基于光动力触发的级联反应核壳复合纳米系统（Arg-PCN@Gel）。该纳米系统可以靶向MRSA的自溶素（atl）而高效黏附于生物被膜，并在MRSA感染部位高表达的金属基质酶的作用下释放内核Arg-PCN。在红光照射下，Arg-PCN@Gel可以通过级联反应产生ROS、RNOS等多种活性物质，并驱动精氨酸产生NO信号分子增强宿主免疫反应，协同预防和杀伤生物膜。复合纳米系统主要通过下调cidA、icaA、arsR、copZ、codY、ccpA等来抑制MRSA的精氨酸代谢系统、金属元素代谢、能量利用效率、双组分系统和EPS的合成，以防止生物膜产生。同时，利用NO高效破坏成熟的生物膜屏障，促进ROS和ONOO-渗透到生物膜中，破坏生物被膜内MRSA的细胞壁和细胞膜。在小鼠生物被膜感染模型中，Arg-PCN@Gel可以靶向生物被膜感染部位并持续停留15天。在治疗初期，复合纳米系统可诱导促炎因子TNF-α和iNOS的高表达，并驱动精氨酸产生大量NO以发挥抗菌效果；在治疗后期，逐渐积累的NO不仅可清除细菌，还可诱导了IL-4和Arg-1等抗炎因子的表达，利用精氨酸从促炎阶段转化为抗炎阶段来促进伤口愈合。本研究为细菌生物被膜感染的治疗提供了高效精准的协同替代治疗方案，为解决生物被膜的治疗难题提供潜在的策略。 Arg-PCN@Gel的制备及其靶向协同光动力疗法和营养免疫疗法的示意图

免疫疗法微生物疗法临床研究

2022-12-15

·GlobeNewswire-Health Care

Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)

SOUTH SAN FRANCISCO, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported today that dosing with ALG-125755, a small interfering RNA (siRNA) targeting the production of hepatitis B surface antigen (HBsAg), was initiated in subjects with chronic hepatitis B (CHB) in Study ALG-125755-501 (NCT05561530). “siRNA drugs targeting HBsAg production have generally been well tolerated and have consistently lowered HBsAg levels, demonstrating the potential to become a cornerstone therapy to achieve functional cure in CHB,” said Lawrence Blatt, Ph.D., MBA, CEO and Chairman of the Board at Aligos. “The team has made excellent progress over the past two months advancing ALG-125755 through the single ascending dose (SAD) portion of the study in healthy volunteers, where doses up to 100 mg have been evaluated. This has enabled us to advance into CHB subjects ahead of schedule. We plan to evaluate additional CHB cohorts receiving single or multiple doses of ALG-125755 throughout the coming year to identify a dose regimen to advance into combination studies. Additionally, we plan to share available study data in healthy volunteers and CHB subjects at scientific conferences throughout 2023.” About Aligos Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

siRNA临床结果

2022-10-24

·BioSpace

ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Hepatitis B Data at AASLD 2022

CONCORD, Mass.--(BUSINESS WIRE)-- ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure in patients chronically infected with Hepatitis B, announced today that two abstracts were accepted for poster presentation at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting, to be held in Washington, DC, USA, November 4 – 8, 2022. “We are excited to continue to make the Hepatitis B community aware of our progress for the therapeutic vaccine candidate CLB-3000, toward first in human trials and our confidence in this novel and differentiated approach” said Aileen Rubio, PhD., CEO for the company. Chronic infection with Hepatitis B (CHB) remains a significant global disease infecting hundreds of millions of people, where functional cure remains elusive and combination therapies are likely needed. We believe that re-education of patients’ immune systems to break tolerance of their chronic HBV infections through administration of ClearB’s therapeutic vaccine could become an important component of combination treatment regimens.” Abstract Number / Poster Number: 36528 / SAT1193 Abstract Title : Evaluation of the Hepatitis B therapeutic vaccine candidate CLB-3000 (CLB-405 + CLB-505 with Alhydrogel): a 9- or 15-week toxicity study in New Zealand White (NZW) rabbits with a 4-week recovery period Date: Friday, 4 November 2022 Time: 12:00 pm EDT Presenter Name: Aileen Rubio, ClearB Therapeutics Abstract Number / Poster Number: 37190 / SAT1215 Abstract Title : Immunogenicity following intramuscular vaccination with increasing dose levels of recombinant Hepatitis B surface antigen (HBsAg) variants CLB-405 and CLB-505 with or without Alhydrogel in New Zealand White (NZW) rabbits Date: Friday, 4 November 2022 Time: 12:00 pm EDT Presenter Name: Aileen Rubio, ClearB Therapeutics For more information regarding AASLD 2022 please visit The Liver Meeting | AASLD About ClearB Therapeutics ClearB Therapeutics was co-founded in 2017 by Morningside Ventures in collaboration with Professor Stephen Locarnini and the Victoria Infectious Diseases Reference Laboratory in Melbourne, Australia. ClearB is working to develop therapeutic vaccines designed to drive functional cure of Hepatitis B. The work is grounded in proprietary insights derived from studying rare-event infection resolution in patients who suffer from chronic Hepatitis B. For more information, please visit . About Morningside Ventures: Morningside was founded in 1986 by the Chan family, to make private equity and venture capital investments in North America, Europe, and Asia Pacific. In the life sciences, Morningside specializes in early-stage (pre-clinical through human proof-of-concept) investments in biopharmaceutical products. They partner with academic founders and entrepreneurs to build world-class companies that want to markedly improve the current state of medicine today and ultimately, the lives of patients. Morningside's focus is to invest in excellent biomedical research, where a significant body of knowledge has been gathered and there is a plausible path forward in clinical development. Their mission is to contribute to making a meaningful, positive impact on the prevention or treatment of human disease, and believe that so long as this is achieved, commercial success will follow.

合作疫苗